INmune Bio (NASDAQ:INMB), a clinical-stage biotechnology company focused on developing immunotherapies for neurodegenerative and inflammatory diseases, released its earnings for the second quarter on August 7, 2025. The primary news was a major net loss, stemming from a $16.5 million impairment charge, and clinical data from its lead XPro program in Alzheimer’s failing primary endpoints in the main patient group. The loss widened from $(0.50) (GAAP) in the prior year. There was no revenue, in line with expectations for a pre-commercial biotech. Overall, the quarter brought major clinical and financial setbacks, with ongoing questions around regulatory timelines and financial sustainability. Cash reserves increased thanks to a new equity raise, giving some operational cushion but keeping capital needs in sharp focus for potential investors.
Source: Analyst estimates for the quarter provided by FactSet.
INmune Bio (NASDAQ:INMB) is developing therapies that leverage the innate immune system—a branch of immunity that forms the body’s first line of defense—to address diseases like Alzheimer’s, various cancers, and rare skin disorders. Its approach targets immune functions not exploited by most rivals, focusing on drugs that neutralize specific inflammation drivers or enhance the activity of “natural killer” (NK) cells in attacking tumors.